CIAM
ADVM

Caitong International Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

Caitong International Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-44
Closed -$205 – 2129
2024
Q4 		$205 Buy
+44
New +$296 ﹤0.01% 1582

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caitong International Asset Management's ADVM Position: Q1 2025 in Review

Caitong International Asset Management sold out of Adverum Biotechnologies (ADVM) in Q1 2025, closing a stake of 44 shares — an estimated $205 sold.

Caitong International Asset Management first reported a position in ADVM in Q4 2024 and held it in 1 quarter. The position peaked at $205 in Q4 2024. 70 funds tracked by Wall St. Rank hold ADVM as of Q1 2025.

  • Caitong International Asset Management reported no remaining Adverum Biotechnologies position as of Q1 2025 after selling out during the quarter.
  • Caitong International Asset Management sold 44 Adverum Biotechnologies shares in Q1 2025, an estimated $205.
  • Caitong International Asset Management first reported a position in Adverum Biotechnologies in Q4 2024 and held it in 1 quarter.
  • Caitong International Asset Management's Adverum Biotechnologies position peaked at $205 in Q4 2024.
  • 70 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2025.

Based on Caitong International Asset Management's 13F filing for Q1 2025, filed 13 May 2025.